Pfizer Inc., Groton, CT, USA.
Leuk Res. 2012 Apr;36(4):438-42. doi: 10.1016/j.leukres.2011.10.011. Epub 2011 Oct 28.
Understanding the impact of second-line tyrosine kinase inhibitor therapy on the health-related quality of life (HRQOL) of imatinib (IM)-resistant and IM-intolerant chronic phase chronic myeloid leukemia (CP CML) patients is important given the increased survival that comes with therapy. As part of a bosutinib single-arm phase 2 trial, 200 IM-resistant and 88 IM-intolerant CP CML patients' HRQOL was assessed prior to and throughout treatment with the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu). Little HRQOL impairment was demonstrated at baseline. Over the course of 96 weeks on bosutinib therapy, patients noted statistically significant and/or clinically meaningful improvements on several FACT-Leu scales.
了解二线酪氨酸激酶抑制剂治疗对伊马替尼（IM）耐药和不耐受的慢性期慢性髓性白血病（CP CML）患者健康相关生活质量（HRQOL）的影响很重要，因为治疗会带来生存时间的延长。在博舒替尼单臂 2 期试验中，在接受博舒替尼治疗之前和整个过程中，对 200 例 IM 耐药和 88 例 IM 不耐受的 CP CML 患者的 HRQOL 进行了评估。在基线时，几乎没有发现 HRQOL 受损。在接受博舒替尼治疗的 96 周期间，患者在几个 FACT-Leu 量表上注意到了统计学上显著和/或临床上有意义的改善。
